NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta
pharmaphorum
APRIL 20, 2021
According to Novartis, Kesimpta is the first targeted B cell therapy for RMS that can be self-administered at home once a month using an autoinjector, avoiding the need for patients to travel to hospital during the pandemic, and easing the pressure on clinicians. billion by 2028. billion in sales in 2028.
Let's personalize your content